# BAYOU (NCT03459846)

> A Study of Durvalumab Alone and Durvalumab+Olaparib in Advanced, Platinum-Ineligible Bladder Cancer (BAYOU)

No report yet. It can be ordered.

- Indication: previously untreated, platinum-ineligible metastatic urothelial carcinoma

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03459846
- Phase: PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: AstraZeneca
- Conditions: Urinary Bladder Neoplasms
- Interventions: Durvalumab; Olaparib; Placebo
- Enrollment: 154
- Primary outcome: Progression-free Survival (PFS)

## Indexed commentary on BAYOU so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 2 posts on X
- 1 YouTube video

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=bayou-nct03459846